Status:

COMPLETED

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

Lead Sponsor:

Pfizer

Conditions:

Major Depression

Eligibility:

All Genders

18+ years

Brief Summary

The primary purpose of this study is to investigate medication utilization pattern and risk of adverse outcomes among commonly used antidepressants by using nationwide claims database, in order to ass...

Detailed Description

While there are many antidepressants from which physicians can select based on efficacy and tolerability profile, evidence on effectiveness and safety outcomes of new antidepressants in real clinical ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
  • Patients aged 18 years or older on the index date
  • Patients who had at least one inpatient claim or two outpatient claims in the intake period with any of the following diagnosis codes F06.3 Organic mood \[affective\] disorders F32\* Depressive episode F33\* Recurrent depressive disorder F34.1 Neurotic depression F38.1 Other recurrent mood \[affective\] disorder F41.2 Mixed anxiety and depressive disorder
  • Patients prescribed any of the following antidepressant during intake period (from January 1, 2017 to June 30, 2018)
  • Exclusion Criteria
  • Patients meeting any of the following criteria will not be included in the study:
  • Patients with a claim of diagnosis codes in Table 1 during the 12 month pre-index period
  • Patients with a claim of prescription in Table 2 during the 12 month pre-index period
  • Patient who had a claim as a beneficiary of Medical Aid program (Korean Medicaid program with free or minimum copay)
  • Patients who are hospitalized at the index date
  • Patients who are under hospice care (procedure codes WG\*-WO\*)

Exclusion

    Key Trial Info

    Start Date :

    July 4 2022

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    November 3 2022

    Estimated Enrollment :

    370212 Patients enrolled

    Trial Details

    Trial ID

    NCT04446039

    Start Date

    July 4 2022

    End Date

    November 3 2022

    Last Update

    December 9 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Pfizer

    Seoul, South Korea